January 2019 PMID 30415602

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Christian T Ruff

Full text PDF Download social card

Mentions

243

Peak: 71 in Jan 2019

across 5 sources since Jan 2019

Extended reach

1,620,717

potential audience

Total likes

360

Video views

1,043

Mentions per month

Jan 2019 – Jun 2025

Where it's discussed

X / Twitter174 posts
News51 articles
Facebook10 posts
Blogs6 articles
YouTube2 videos

AI synopsis

What people are saying

The overall tone suggests a balanced view, with many posts emphasizing lower risks of heart failure and renal benefits, such as 'Dapagliflozin was associated with lower risk of CV death or hospitalizations for HF,' and discussing safety concerns like 'Genital infections were higher with Dapagliflozin.' Words like 'linked to lower risk' and 'safety profile' highlight cautious optimism, while mentions of 'no significant difference in major events' show a nuanced understanding of the study's scope and limitations.

AgreementModerate agreement

Most discussions acknowledge the study's findings that dapagliflozin lowers cardiovascular death and heart failure hospitalizations, though some note it does not significantly change major cardiac event rates.

InterestHigh interest

Social discussions demonstrate high curiosity, with numerous posts referencing the trial's results, safety profile, and clinical implications, indicating strong relevance to clinicians and researchers.

EngagementModerate engagement

Many comments delve into specific outcomes, safety details, and related studies, reflecting moderate to deep engagement, although some posts are simply sharing or summarizing without critical analysis.

ImpactModerate impact

While some comments suggest the research reinforces existing clinical notions, few express expectations of a transformative impact, indicating a perception of moderate influence overall.

Abstract in brief

Dapagliflozin is a medication that helps lower blood sugar in people with type 2 diabetes by promoting sugar excretion through urine, and its effects on heart health were studied in a large clinical trial.
The study found that dapagliflozin was safe, as it did not increase major cardiovascular events compared to placebo, and it significantly reduced the risk of hospitalization for heart failure and some kidney-related problems.
While dapagliflozin did not significantly lower overall major adverse cardiovascular events, it showed benefits in reducing heart failure hospitalizations and protecting kidney function, making it a potentially useful treatment option for people with type 2 diabetes at risk for heart and kidney issues.]

Read the full abstract

All mentions

Key Cardiological Trials Impacting 2018 Outcomes

This video reviews the top 10 cardiology trials of 2018, highlighting significant studies including those on PCI strategies in cardiogenic shock and the effects of various treatments on cardiovascular outcomes. Discover…

CardioLearning · Jan 8, 2019 969 views

Advances in Managing Cardiovascular and Kidney Risks in Type 2 Diabetes

This episode explores strategies for managing cardiovascular benefits in patients with type 2 diabetes. Host Dr. Silvio Inzucchi and cardiologist Dr. Mikhail Kosiborod discuss the latest approaches, including the role…

Medscape · Feb 25, 2025 74 views

高橋△

@ri_kai · X

RT @enango: NEJM/RCT（DECLARE–TIMI 58）．SGLT-2阻害薬Dapagliflozin（フォシーガ）は2型糖尿病の心不全増悪による入院を減らすが，心血管イベント，心血管死亡，総死亡を減らさず．https://t.co/vB8rfmFaWX

Jun 13, 2025 · 10 shares · 590 followers View post →

Syed Shahrul Naz

@drshahrul80 · X

RT @EndoDialogues: 2019: DECLARE-TIMI 58 Tested dapagliflozin non-inferiority for CV outcomes in pts with T2DM. Population with fewer ris…

Jun 5, 2024 · 1 share · 6,927 followers View post →

Endocrine dialogues

@EndoDialogues · X

Jun 4, 2024 · 9 likes · 1 share · 6,468 followers View post →

د.عبدالرحمن جوهرجي

@drjoharji1 · X

في دراسة الفورسيجا على سلامة القلب الي تدعى declare timi trial https://t.co/RvDkW0FkDk كان الدواء آمن على القلب لكن لم يكن هنالك فوائد اضافية في الحماية من الجلطات ولعل السبب هو تصميم الدراسة والعينة المستخدمة اغلبهم غير مصابين مسبقا بمشاكل في القلب عكس دراسة الجارديانس https://t.co/x8ICSTbmY5

Nov 20, 2022 · 1 like · 88,968 followers View post →

Muhammad Tahir

@tauhair · X

RT @mendesthiagob: 2019: DECLARE-TIMI 58 Tested dapagliflozin non-inferiority for CV outcomes in pts with T2DM. Population with fewer risk…

Oct 30, 2022 · 1 share · 239 followers View post →

Endocrine dialogues

@EndoDialogues · X

Oct 29, 2022 · 27 likes · 1 share · 6,468 followers View post →

Tá de Clinicagem - TdC

@tadeclinicagem · X

DECLARE- TIMI 58 Ensaio clínico em pacientes com DM2 e HbA1c entre 6,5% e 12%, TFG > 60 e evento cardiovascular prévio ou múltiplos fatores de risco Dapaglifozina 10 mg/dia x placebo Redução da combinação morte cardiovascular + internações por IC https://t.co/11BX9GF4vE

Jun 14, 2022 · 1 like · 11,988 followers View post →

cardio-met

@cardiomet_CE · X

24b) Other #DPP4i, #basal #insulin, and α-GI are neutral but and @GLP1 RAs have modest benefit from meta-analysis. #SGLT2i show consistent and robust benefits. Consider

May 11, 2022 · 3 likes · 4,216 followers View post →

The Cardiometabolic Forum

@theCMforum · X

Wiviott et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. @NEJM 2019. View the summary here: https://t.co/VOfmAKLIEN

Feb 17, 2022 · 256 followers View post →

MacroFour

@MacroFour · X

@FrogHarmless @Tom_Babington1 @Nickle1011 @OlivePufa DECLARE-TMI https://t.co/ImHsdDwJJU

Nov 8, 2021 · 6,063 followers View post →

Sammy Jimenez

@nicoleejimenez1 · X

Dapagliflozin and cardiovascular outcomes in type 2 diabetes https://t.co/JTKQE3U84Q

Jun 3, 2021 · 8 likes · 5 followers View post →

Adenosina

@Adenosina11 · X

RT @el_internista: Y ahora, algo de medicina basado en evidencia. Estudio DECLARE TIMI 58 Dapagliflozina y riesgo cardiovascular. ** TIENEN…

Apr 7, 2021 · 3 shares · 4,695 followers View post →

Yasser UMKCRCT

@ymhs92 · X

DECLARE–TIMI 58: Dapagliflozin was associated with lower risk of CV death or hospitalizations for HF, as well as lower renal events compared to placebo. Genital infections were higher with Dapagliflozin #UMKCRCT https://t.co/w7aJh4mG0y

Mar 20, 2021 · 10 followers View post →

EURORECKD

@euroreckd · X

RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…

Feb 24, 2021 · 7 shares · 174 followers View post →

Dr. Carlos Orantes

@nefrorantes · X

RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…

Feb 24, 2021 · 7 shares · 5,015 followers View post →

Rayhan

@Nephwizard · X

RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…

Feb 24, 2021 · 7 shares · 170 followers View post →

Angel Cesar Ortiz

@AngelCesarOrtiz · X

RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…

Feb 24, 2021 · 7 shares · 1,002 followers View post →

carmen torres

@tatatorres1515 · X

RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…

Feb 24, 2021 · 7 shares · 611 followers View post →

Fundación Renal Española

@FundacionRenalE · X

RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…

Feb 24, 2021 · 7 shares · 3,911 followers View post →

Int Society of Nephrology

@ISNkidneycare · X

#ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further reading: https://t.co/gZYEfZthJV https://t.co/pxg7VuTPmM https://t.co/TkL1bUZAzh https://t.co/jiReouHd2o https://t.co/afT6tGHSqa https://t.co/0aWpT6gJc6 https://t.co/KSEVGqkcZD

Feb 24, 2021 · 13 likes · 7 shares · 29,417 followers View post →

Génesis Salvador

@GnesisSalvador5 · X

Dapagliflozin and Cardiovascular outcomes in Type 2 Diabetes Please like and comment! https://t.co/CYY4kkyKgm

Feb 17, 2021 · 20 likes View post →

Daniel

@dmoriitta · X

RT @MiurielMora: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Miuriel Mora - Paralelo D https://t.co/nFO2YjNX4o

Nov 11, 2020 · 2 shares · 21 followers View post →

Jehnevid

@Jeehncrys · X

RT @MiurielMora: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Miuriel Mora - Paralelo D https://t.co/nFO2YjNX4o

Nov 11, 2020 · 2 shares · 1,503 followers View post →

@Miuriel.mora

@MiurielMora · X

Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Miuriel Mora - Paralelo D https://t.co/nFO2YjNX4o

Nov 11, 2020 · 32 likes · 2 shares · 7 followers View post →

Dr.AdnanKhanFanPage.

@AdnankhanFan · X

RT @Dr_Khan: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/WthPeGAGwh https://t.co/VQawT0xbVt

Nov 11, 2020 · 2 shares · 2,936 followers View post →

Pearl

@Lynchdom3 · X

RT @Dr_Khan: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/WthPeGAGwh https://t.co/VQawT0xbVt

Nov 10, 2020 · 2 shares · 984 followers View post →

Dr. Adnan Khan

@Dr_Khan · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/WthPeGAGwh https://t.co/VQawT0xbVt

Nov 10, 2020 · 13 likes · 2 shares · 62,979 followers View post →

たけちゃん

@nitrotake · X

珍しくダパグリフロジンのメーカー勉強会だったんだけど、DAPA-HF(PMID:31535829)やるのかな？と思ったら違った。案の定、複合アウトカムの紹介だけだった。 https://t.co/nWQgDXRWQs

Nov 9, 2020 · 1,442 followers View post →

Allison Cabrera

@allisoncc97 · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/G8OEZBukhC via @YouTube

Nov 5, 2020 · 15 likes · 2 followers View post →

Taher Modarressi, MD

@tmodarressi · X

@DrAMcCullough @mvaduganathan @sameerbansilal @andrewwsteele Interesting q. I am a big proponent of many non-TG feedback mechs. There may be an eventual limit but so far the data has been consistent and arguably better even as the pt pop has gotten sicker. Take CVD/HHF outcome for e.g.: DECLARE (https://t.co/LSjJnY5OCp) CVD/HHF HR was

Aug 30, 2020 · 2 likes · 1,711 followers View post →

movedoc

@movedoc · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/N9JHDYiODq

Feb 13, 2020 · 486 followers View post →

Marta Varas❣️

@VarasMayoral · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 30, 2020 · 8 shares · 296 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 29, 2020 · 8 shares · 3,599 followers View post →

Chema Fernandez

@chemachir · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 26, 2020 · 8 shares · 3,868 followers View post →

zaida

@zaidacs · X

RT @Pablomatsol: Reducción de mortalidad CV y de IC... No tenéis vosotros ningún paciente de estas características en la urgencia? Quizá es…

Jan 26, 2020 · 3 shares · 119 followers View post →

Ana Piera #JuntosEsMasFacil

@ana_apiecar · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 26, 2020 · 8 shares · 2,575 followers View post →

Javier Carrasco, PhD

@fjcarrascos · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 25, 2020 · 8 shares · 1,311 followers View post →

Lorenzo Bertomeu

@ManuduManuel · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 25, 2020 · 8 shares · 3,599 followers View post →

Juani Carretero Gomez

@CarreteroJuani · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 25, 2020 · 8 shares · 2,149 followers View post →

Jose Carlos Arevalo

@joscarlor2 · X

RT @Diabetes_SEMI: 1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Dismin…

Jan 25, 2020 · 8 shares · 760 followers View post →

GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI

@Diabetes_SEMI · X

1⃣No inferioridad frente a placebo en la reducción del objetivo MACE (muerte cardiovascular, infarto e ictus). 2⃣Disminución de muerte cardiovascular y hospitalización por insuficiencia cardiaca 3⃣Reducción de ERC https://t.co/xPiWIU902Q #14DM_SEMI https://t.co/9HrYo218fJ

Jan 25, 2020 · 8 likes · 8 shares · 6,346 followers View post →

M. Pilar López

@MPilarLpez1 · X

RT @Pablomatsol: Reducción de mortalidad CV y de IC... No tenéis vosotros ningún paciente de estas características en la urgencia? Quizá es…

Jan 24, 2020 · 3 shares · 1,375 followers View post →

Pere Llorens

@LlorensPere · X

RT @Pablomatsol: Reducción de mortalidad CV y de IC... No tenéis vosotros ningún paciente de estas características en la urgencia? Quizá es…

Jan 24, 2020 · 3 shares · 3,636 followers View post →

Pablo Matías Soler

@Pablomatsol · X

Reducción de mortalidad CV y de IC... No tenéis vosotros ningún paciente de estas características en la urgencia? Quizá es el momento de empezar a utilizar este tipo de fármacos desde nuestras UCEs/observaciones... https://t.co/BxEbxB76B8 https://t.co/RMo30PXrlB

Jan 24, 2020 · 5 likes · 3 shares · 396 followers View post →

Martín López de la Torre

@elendocrino · X

RT @rincondesisifo: (Píldoras) Evaluación crítica del DECLARE TIMI 58 https://t.co/WqMwmFtYdt Y así lo vimos nosotros... https://t.co/ebl…

Nov 10, 2019 · 5 shares · 2,965 followers View post →

Raj Mehta

@raj_mehta · X

RT @AnilMakam: 1| The DECLARE-TIMI 58 trial is out in @NEJM which studies effect of dapagliflozin on cardiovascular outcomes in type 2 #dia…

Nov 4, 2019 · 18 shares · 2,135 followers View post →

Inmaculada Plasencia

@iplagar · X

RT @rincondesisifo: (Píldoras) Evaluación crítica del DECLARE TIMI 58 https://t.co/WqMwmFtYdt Y así lo vimos nosotros... https://t.co/ebl…

Nov 1, 2019 · 5 shares · 462 followers View post →

Mª Victoria Cózar

@MVictoriaCL · X

RT @rincondesisifo: (Píldoras) Evaluación crítica del DECLARE TIMI 58 https://t.co/WqMwmFtYdt Y así lo vimos nosotros... https://t.co/ebl…

Nov 1, 2019 · 5 shares · 259 followers View post →

MarionaNadal

@manallo78 · X

RT @rincondesisifo: (Píldoras) Evaluación crítica del DECLARE TIMI 58 https://t.co/WqMwmFtYdt Y así lo vimos nosotros... https://t.co/ebl…

Oct 30, 2019 · 5 shares · 386 followers View post →

rincondesisifo

@rincondesisifo · X

(Píldoras) Evaluación crítica del DECLARE TIMI 58 https://t.co/WqMwmFtYdt Y así lo vimos nosotros... https://t.co/eblOb6MQq6 https://t.co/YelbOdSfmf

Oct 30, 2019 · 4 likes · 5 shares · 8,445 followers View post →

Eduardo Puerta

@melmack2k · X

"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (Viñeta del ensayo clinico)" https://t.co/of7BMHXPpS #blogpersonales de medicina #feedly

Oct 24, 2019 · 785 followers View post →

Saludteca

@Saludteca · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (Viñeta del ensayo clinico) https://t.co/2m0ejEntRu

Oct 24, 2019 · 1,998 followers View post →

たけちゃん

@nitrotake · X

だぱの文献 https://t.co/RRidL95BuT

Oct 2, 2019 · 1,442 followers View post →

KristopherMaday PA-C

@PA_Maday · X

DECLARE-TIMI Trial Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/u5qFRzDTg2 https://t.co/CeS0Flx8kZ

Sep 22, 2019 · 1 like · 2,453 followers View post →

Prime

@PrimeGlobalBuzz · X

A drug used to successfully treat type 2 diabetes can also be effective to treat heart failure, researchers find. @NEJM #Diabetes #HeartFailure #Pharma https://t.co/4Gg9if3jLc

Sep 20, 2019 · 888 followers View post →

Dr. Hanma

@Edd_G10 · X

RT @el_internista: Y ahora, algo de medicina basado en evidencia. Estudio DECLARE TIMI 58 Dapagliflozina y riesgo cardiovascular. ** TIENEN…

Aug 19, 2019 · 3 shares · 330 followers View post →

el_internista

@el_internista · X

Aug 19, 2019 · 26 likes · 3 shares · 9,313 followers View post →

Michael Fralick

@FralickMike · X

@Derek_Leong_RPh @krychtiukmd @BiancaItariu @pabeda1 @SABOURETCardio @PabloJ @rafavidalperez @MihaiTrofenciuc @ShelleyZieroth @JGrapsa @AndreasGevaert @Ana_Viana_T @Pete_Wu @DavidJuurlink @Rene_Wong I'm late to the party! You are right it's relatively rare (RR=2, Absolute Risk is < 1%). Here's snapshot of the literature, two observational studies: https://t.co/0p2g5BIyjK & https://t.co/8KcGCR406S & now 2 RCTs https://t.co/IFymIT8aK9 & https://t.co/aruToEIbvH.

Aug 16, 2019 · 3 likes · 4,000 followers View post →

Photis Constantinou

@photiscon · X

It looks like SGLT2-inhibitors might not increase amputation risk after all. DECLARE TIMI 58 for dapagliflozin showed no increased risk for amputation and the CV benefit for patients with PAD was greater! https://t.co/16AdJJBfw1

Jul 29, 2019 · 4 likes · 15 followers View post →

Antonio Manteca

@amango30 · X

RT @RevistaMFSamfyc: Dapagliflozina y resultados cardiovasculares en la diabetes tipo 2 https://t.co/pYrXntIWrP PMID 31067395

Jul 5, 2019 · 1 share · 138 followers View post →

Revista MFAndalucia

@RevistaMFSamfyc · X

Dapagliflozina y resultados cardiovasculares en la diabetes tipo 2 https://t.co/pYrXntIWrP PMID 31067395

Jul 1, 2019 · 2 likes · 1 share · 722 followers View post →

Jeremy Sussman

@JeremySussman · X

@mikejohansenmd @raj_mehta @Info_Mastery @ProfHayward OK, I just looked through NEJM for 2019. Most of these aren't vital, but they're probably good for an FP to know about, a few are important: https://t.co/IRC7l0gQZ2 https://t.co/fGYtFiFLGd https://t.co/1pF2KaG8w9 https://t.co/lLVVWBuRlb https://t.co/w1iAnfPBQJ

Jun 21, 2019 · 1 like · 1,942 followers View post →

Allied Conferences

@alliedmeet · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. To know more: https://t.co/mo7QhHgADf #cardiacconference #cardiacsurgery #cardiologymeeting #heartproblem #Taiwan #cardiology #cardiologists #alliedacademies #conferences #diabetes #cardio #heart https://t.co/cbTMUXT2JF

May 20, 2019 · 850 followers View post →

Cardiac Surgery Congress

@CongressCardiac · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes To know more: https://t.co/KBSqlAIYdz #cardiacconference #cardiacsurgery #cardiologymeeting #heartproblem #Taiwan #cardiology https://t.co/W3TxVUYJ70

May 15, 2019 · 153 followers View post →

Dr Jean Pierre Laroche #vacciné 6.0

@Echoraljpangio · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/NvxaGxTZ7B

May 9, 2019 · 2,716 followers View post →

Anamaria Cl. Pharmacology

@ClPharmacology · X

RT @dr_ezquerra: ¿Qué hubo relevante en 2018 sobre CARDIOLOGÍA? Estudio DECLARE TIMI 58: ¿Dapaglifozin disminuye el riesgo de insuficiencia…

May 7, 2019 · 1 share · 66 followers View post →

Ana Maria Matias

@AMCMA6 · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 25, 2019 · 10 shares · 313 followers View post →

KIN LOPEZ

@KINWAHSIU · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 24, 2019 · 10 shares · 188 followers View post →

Carlos Cortés, MD FACP FASN

@Kidney_wiz · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 23, 2019 · 10 shares · 447 followers View post →

salman hussain

@salmanjamia · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 23, 2019 · 10 shares · 62 followers View post →

Dr. Padmini sirkanungo

@drpadmini_s · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 23, 2019 · 10 shares · 174 followers View post →

Vivekanand Jha | विवेकानन्द झा

@vjha126 · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 23, 2019 · 10 shares · 5,611 followers View post →

Tired & Sakit

@tulunsokit · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 22, 2019 · 10 shares · 3,725 followers View post →

Rosina Dal Maso

@MasoRosina · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 22, 2019 · 10 shares · 58 followers View post →

Sunil Badve

@Badves · X

RT @brendonneuen: Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESK…

Apr 22, 2019 · 10 shares · 1,331 followers View post →

Brendon Neuen

@brendonneuen · X

Don’t forget the 3rd CVOT DECLARE - 47% relative risk reduction in the renal composite (sustained 40% decline in eGFR/ESKD/renal death) https://t.co/73mGK1G7El https://t.co/gEEeL2tHlC

Apr 22, 2019 · 29 likes · 10 shares · 4,698 followers View post →

PONCH

@drponch · X

RT @sotoO1o: @pabloange Dapagliflozina también mostró efecto positivo en desenlaces renales en DECLARE-TIMI 58 en enero de este año doi:10.…

Apr 17, 2019 · 1 share · 1,079 followers View post →

Javier Soto

@sotoO1o · X

@pabloange Dapagliflozina también mostró efecto positivo en desenlaces renales en DECLARE-TIMI 58 en enero de este año doi:10.1056/NEJMoa1812389 https://t.co/uNbLm2T1JO

Apr 16, 2019 · 2 likes · 1 share · 606 followers View post →

Larronde Esteban

@EstebanDL · X

@alavallecobo @jpcostabel @CMGarmendia @MariaSolAndres1 @FedeMachadoG @ezeforte @KohanAndres @pbaglioni @mirzarivero @alavallecobo , fijatre si encontras ese... https://t.co/fHOpdz68qn https://t.co/h5VjJmvVmf

Mar 25, 2019 · 2 likes · 23,860 followers View post →

myendoconsult

@myendoconsult · X

DECLARE Trial. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. #diabetes #heartfailure #CVOTs #AACE #ENDO2019 https://t.co/lpFxpvPzDp

Mar 24, 2019 · 19 followers View post →

myendoconsult

@myendoconsult · X

DECLARE Trial. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. #diabetes #heartfailure #CVOTs #AACE #ENDO2019 https://t.co/mEZGtwAmWz

Mar 23, 2019 · 19 followers View post →

David A. Cohen

@DavidACohen_MD · X

15/15 Links to citations: https://t.co/MVMmAtpIaf https://t.co/PY4Dn6X9Bn https://t.co/VX44qck2n2 https://t.co/s2GQbKKI3R https://t.co/meSES5A9HF https://t.co/Poio86DZ74 https://t.co/aneU63NacY

Mar 3, 2019 · 3 likes · 2,517 followers View post →

MY@MD.,PhD.

@MD_fuk · X

フォシーガ 40歳以上の心血管疾患の既往・動脈硬化リスク因子を複数もつ糖尿病患者に対して心不全の入院や心血管死亡を低下、糖尿病性腎症の発症を抑制。死亡率や主要心血管イベントの発生に有意な差はなく、足の壊疽の増加もなし。 DECLARE-TIMI58 trial https://t.co/rsSAwjnaoc

Feb 20, 2019 · 1 like · 1,446 followers View post →

Feedkast Medical

@FeedkastMedical · X

This week's #trending article in our #T2D feed is 'Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes' from @NEJM https://t.co/diruMO89CE Check out our feed for more #diabetes stories in our feed➡️ ➡️ https://t.co/rwLNrJsbOr

Feb 19, 2019 · 445 followers View post →

Emtiro Health

@EmtiroHealth · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/f9YaZUc2M4

Feb 14, 2019 · 108 followers View post →

Shinya Goto

@sgoto4 · X

RT @TIMIStudyGroup: Now out in print in @NEJM --> Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/yWohJAhIyv @swi…

Feb 12, 2019 · 4 shares · 325 followers View post →

Mountaineer

@mount4ineer · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 6, 2019 · 17 shares · 55 followers View post →

Rosy

@rosileealvarez · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/H6HlLMKURo

Feb 6, 2019 · 322 followers View post →

Enrique Santas

@SantasEnrique · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 6, 2019 · 17 shares · 5,538 followers View post →

Dr Akhlaque Uddin

@UddinAkhlaque · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 920 followers View post →

めだか

@kiiui555 · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 42 followers View post →

serrgv

@serrgv · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 145 followers View post →

Paco Valls

@pacovr53 · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 2,646 followers View post →

Dr. CZ

@AngelMD1103 · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 72,983 followers View post →

KGH Library Service

@KGHNHSLibrary · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 602 followers View post →

Dr. Sue Gross

@DrSueGross · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 3,032 followers View post →

The ObG Project

@TheObGProject · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 9,003 followers View post →

mamylona

@mamylona1 · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 65 followers View post →

Javier Carrera

@Javier_CarreraH · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 1,830 followers View post →

Pub Health Monitor

@monitor_PH · X

RT @NEJM: From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 http…

Feb 5, 2019 · 17 shares · 1,822 followers View post →

NEJM

@NEJM · X

From Pages to Practice: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/hZY2i61SVf via @NEJMres360 https://t.co/glNZTSczzb

Feb 5, 2019 · 34 likes · 17 shares · 935,580 followers View post →

Salud juntos

@alfonso_casi · X

Dapagliflozina y resultados cardiovasculares en la diabetes tipo 2: no produce mayor o menor tasa de eventos cardiovasculares mayores que el placebo, pero sí menor mortalidad cardiovascular u hospitalización por insuf cardíaca. https://t.co/lgmt3ktAdj

Feb 4, 2019 · 8,559 followers View post →

Alosa Health

@AlosaHealth · X

Dapagliflozin (Farxiga) for diabetes doesn’t reduce cardiovascular events but does lower the risk of cardiac death and heart failure hospitalization. @NEJM https://t.co/57pEHHMev6

Feb 1, 2019 · 252 followers View post →

Ivan Mendoza

@mencardio · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Feb 1, 2019 · 39 shares · 7,243 followers View post →

Dispense Marketing

@dispense_rx · X

Dapagliflozin and cardiovascular outcomes in type 2 diabetes https://t.co/Re5OcQABA9

Jan 31, 2019 · 7,002 followers View post →

Rising Stars

@risingstarsgdps · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla con los Safety Events, nos da mucha seguridad (también extravascular) los datos de 17.160…

Jan 31, 2019 · 10 shares · 853 followers View post →

Rising Stars

@risingstarsgdps · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla DECLARE con los resultados de eficacia clave y sus componentes individuales https://t.co/…

Jan 31, 2019 · 16 shares · 853 followers View post →

Rising Stars

@risingstarsgdps · X

RT @CristobMorales: https://t.co/IumWybUOBB Resultados DECLARE con (A)Muerte CV

Jan 31, 2019 · 9 shares · 853 followers View post →

Rising Stars

@risingstarsgdps · X

RT @CristobMorales: https://t.co/IumWybUOBB Características basales de los pacientes con DAPA incluidos en #DECLARE 64años IMC:32,1Kg/m2, D…

Jan 31, 2019 · 14 shares · 853 followers View post →

@CarlosGR82 · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 31, 2019 · 39 shares · 406 followers View post →

Ana Cebrián

@anicebrian · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 31, 2019 · 39 shares · 1,623 followers View post →

Ves Dimov, M.D.

@DrVes · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/6XEtqtx2pf - No change in major adverse cardiovascular events (MACE)

Jan 30, 2019 · 13,916 followers View post →

UMKC Biomedical & Health Informatics

@UMKCInformatics · X

RT @BahaaShq: @UMKCBioMed A very interesting article highlighting the result of randomized trial of patients with type 2 Diabetes treated w…

Jan 30, 2019 · 1 share · 406 followers View post →

The Phlegmfighter

@phlegmfighter · X

@ADAlthousePhD here in @NEJM is another safety #NIFT #noninferiority trial originally designed to exclude a small increase in #MACE for a diabetes drug. There are a ton of these #FDA mandated trials coming out - for DM drugs and asthma inhalers https://t.co/uMwTf6eGrz

Jan 30, 2019 · 7,261 followers View post →

Antonio Manteca

@amango30 · X

RT @RevistaMFSamfyc: Dapagliflozina y efectos cardiovasculares en la diabetes tipo 2 https://t.co/pYrXnu0xjn PMID 30415602

Jan 30, 2019 · 1 share · 138 followers View post →

Revista MFAndalucia

@RevistaMFSamfyc · X

Dapagliflozina y efectos cardiovasculares en la diabetes tipo 2 https://t.co/pYrXnu0xjn PMID 30415602

Jan 30, 2019 · 1 like · 1 share · 722 followers View post →

Bahaa Mustafa

@BahaaShq · X

@UMKCBioMed A very interesting article highlighting the result of randomized trial of patients with type 2 Diabetes treated with Dapagliflozin resulted in lower rate of cardiovascular death and hospitalization of heart failure than placebo #UMKCRCT https://t.co/WfSuL8zBMX … https://t.co/aq31dCt7QG

Jan 30, 2019 · 1 like · 1 share · 50 followers View post →

Otago Medicine

@OtagoMedDept · X

5pm #takehomemessage: "In patients with type 2 #diabetes, at risk for atherosclerotic CVD, treatment with dapagliflozin did not result in a higher or lower rate of MACE, but did result in a lower rate of cv-death or hospitalization for heart failure." https://t.co/fQ6Q4RW4y7

Jan 29, 2019 · 966 followers View post →

Pharmacy Edge

@PharmacyEdge1 · X

Dapagliflozin and cardiovascular outcomes in type 2 diabetes https://t.co/tCT2q4rnLR

Jan 29, 2019 · 1,280 followers View post →

John Fetse

@JohnFetse · X

Treatment with dapagliflozin in type II diabetes does not result in a higher or lower rate of major adverse cardiac events than placebo but results in a lower rate of cardiovascular death. https://t.co/sSMkMpzPJ4 #UMKCRCT https://t.co/DeHoTllw8G

Jan 29, 2019 · 2 likes · 6 followers View post →

かわうそ@知るも知らぬも

@kawauso_srmsrnm · X

お疲れ様です。今日の勉強会のお題は、NEJMの原著論文より、2 型糖尿病におけるダパグリフロジン（フォシーガ）と心血管転帰、でした。なんかあやふやな印象を受ける結果でした。珍しくNNTも明記されていないですし。 https://t.co/EKbsTl9yev

Jan 29, 2019 · 73 followers View post →

Legemiddelhåndboken

@Legemiddelhndb1 · X

Dapagliflozin påvirket ikke forekomsten av iskemisk hjertesykdom hos type 2 diabetikere men resulterte i færre dødsfall relatert til hjertesvikt og færre sykehusinnleggelser, viser ny studie, https://t.co/2vNDAgOsRf i @NEJM Les mer om Dapagliflozin her: https://t.co/Xiq9MGV6eS

Jan 28, 2019 · 92 followers View post →

C.H.B

@chblancher · X

RT @c_allix: Dr Didier Gouet was part of the DECLARE–TIMI 58 investigators who evaluated the cardiovascular safety profile of dapagliflozin…

Jan 28, 2019 · 2 shares · 953 followers View post →

Hôpitaux La Rochelle Ré Aunis

@GHLaRochelle · X

RT @c_allix: Dr Didier Gouet was part of the DECLARE–TIMI 58 investigators who evaluated the cardiovascular safety profile of dapagliflozin…

Jan 28, 2019 · 2 shares · 2,898 followers View post →

Caroline

@c_allix · X

Dr Didier Gouet was part of the DECLARE–TIMI 58 investigators who evaluated the cardiovascular safety profile of dapagliflozin https://t.co/c2l3FDEJy5

Jan 28, 2019 · 2 likes · 2 shares · 25 followers View post →

GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI

@Diabetes_SEMI · X

RT @CristobMorales: https://t.co/IumWybUOBB Características basales de los pacientes con DAPA incluidos en #DECLARE 64años IMC:32,1Kg/m2, D…

Jan 27, 2019 · 14 shares · 6,346 followers View post →

sara artola

@saraartola1 · X

RT @CristobMorales: https://t.co/IumWybUOBB Características basales de los pacientes con DAPA incluidos en #DECLARE 64años IMC:32,1Kg/m2, D…

Jan 27, 2019 · 14 shares · 1,310 followers View post →

Miguel Turégano

@tureyedro · X

RT @CristobMorales: https://t.co/IumWybUOBB Características basales de los pacientes con DAPA incluidos en #DECLARE 64años IMC:32,1Kg/m2, D…

Jan 27, 2019 · 14 shares · 817 followers View post →

Fco Carramiñana Barrera

@fcbzafra · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla con los Safety Events, nos da mucha seguridad (también extravascular) los datos de 17.160…

Jan 27, 2019 · 10 shares · 2,741 followers View post →

Fco Carramiñana Barrera

@fcbzafra · X

RT @CristobMorales: https://t.co/IumWybUOBB Resultados DECLARE con (A)Muerte CV

Jan 27, 2019 · 9 shares · 2,741 followers View post →

Fco Carramiñana Barrera

@fcbzafra · X

RT @CristobMorales: https://t.co/IumWybUOBB Características basales de los pacientes con DAPA incluidos en #DECLARE 64años IMC:32,1Kg/m2, D…

Jan 27, 2019 · 14 shares · 2,741 followers View post →

Martín López de la Torre

@elendocrino · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 27, 2019 · 39 shares · 2,965 followers View post →

David Rodrigues

@davsrodrigues · X

Dapagliflozina vs placebo em #diabetes com factores de risco CV: - não reduz taxa de eventos CV major - reduz taxas de hospitalização por insuficiência cardíaca https://t.co/jY7JpCMIap #evidentiamedica

Jan 27, 2019 · 1,988 followers View post →

latitud0scura

@latitud0scura · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 27, 2019 · 39 shares · 143 followers View post →

Sociedad Valenciana de Nefrología

@SVNefro · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 27, 2019 · 39 shares · 6,138 followers View post →

@ReecesPiecesDiabetes

@ReecesPiecesDi · X

Saturday's daily piece highlights findings of dapagliflozin and cardiovascular outcomes in persons with Type 2 diabetes. Please click below to learn more. @mandy_reece https://t.co/xf3t1MEq17

Jan 26, 2019 · 1 like · 328 followers View post →

Ajar Kochar

@Ajar_Kochar · X

RT @AnilMakam: 1| The DECLARE-TIMI 58 trial is out in @NEJM which studies effect of dapagliflozin on cardiovascular outcomes in type 2 #dia…

Jan 26, 2019 · 18 shares · 3,211 followers View post →

Alejandro I. Pérez Cabeza

@alejandroipc2 · X

RT @AnilMakam: 1| The DECLARE-TIMI 58 trial is out in @NEJM which studies effect of dapagliflozin on cardiovascular outcomes in type 2 #dia…

Jan 26, 2019 · 18 shares · 1,167 followers View post →

maría marques vidas

@mmvidas · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla con los Safety Events, nos da mucha seguridad (también extravascular) los datos de 17.160…

Jan 26, 2019 · 10 shares · 2,358 followers View post →

maría marques vidas

@mmvidas · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 26, 2019 · 39 shares · 2,358 followers View post →

Juani Carretero Gomez

@CarreteroJuani · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla DECLARE con los resultados de eficacia clave y sus componentes individuales https://t.co/…

Jan 26, 2019 · 16 shares · 2,149 followers View post →

Juan Manuel Hernandez

@JuanmaHernande · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 26, 2019 · 39 shares · 281 followers View post →

Juan Manuel Núñez

@Juanma_JMNC · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla DECLARE con los resultados de eficacia clave y sus componentes individuales https://t.co/…

Jan 26, 2019 · 16 shares · 91 followers View post →

GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI

@Diabetes_SEMI · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla DECLARE con los resultados de eficacia clave y sus componentes individuales https://t.co/…

Jan 26, 2019 · 16 shares · 6,346 followers View post →

Chema Fernandez

@chemachir · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla DECLARE con los resultados de eficacia clave y sus componentes individuales https://t.co/…

Jan 26, 2019 · 16 shares · 3,868 followers View post →

Diego Bellido

@DiegoBellido2 · X

RT @CristobMorales: https://t.co/IumWybUOBB Tabla DECLARE con los resultados de eficacia clave y sus componentes individuales https://t.co/…

Jan 26, 2019 · 16 shares · 8,218 followers View post →

OCPhA

@OCPhA_CA · X

Dapagliflozin and cardiovascular outcomes in type 2 diabetes https://t.co/aq0d6DXfQ1 #pharmacist #pharmacy #health #healthcare

Jan 26, 2019 · 252 followers View post →

Dr. Osmar Perez S.

@osmarperse · X

RT @CristobMorales: https://t.co/IumWybUOBB publicación de hoy 24enero19 en NEJM con los datos de Dapagliflozina en el estudio de seguridad…

Jan 25, 2019 · 39 shares · 2,467 followers View post →

Brittany Dingler

@bdingler_PA · X

RT @TIMIStudyGroup: Now out in print in @NEJM --> Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/yWohJAhIyv @swi…

Jan 25, 2019 · 4 shares · 73 followers View post →

Ritu Thamman MD

@iamritu · X

RT @AnilMakam: 1| The DECLARE-TIMI 58 trial is out in @NEJM which studies effect of dapagliflozin on cardiovascular outcomes in type 2 #dia…

Jan 25, 2019 · 18 shares · 31,829 followers View post →

leo uzych

@LeoUzych · X

#Dapagliflozin and #Cardiovascular Outcomes in Type 2 #Diabetes | #NEJM https://t.co/1Ok8yYXno9

Jan 25, 2019 · 222 followers View post →

Garcia Pinilla

@marlucale37 · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 25, 2019 · 7 shares · 1,140 followers View post →

Juan Manuel Hernandez

@JuanmaHernande · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 7 shares · 281 followers View post →

Ivan Mendoza

@mencardio · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 7 shares · 7,243 followers View post →

Raj Mehta

@raj_mehta · X

RT @medrants: #5goodminutes today focuses on a topic that greatly interests #KashlakChief Dapagliflozin and Cardiovascular Outcomes in Type…

Jan 24, 2019 · 5 shares · 2,135 followers View post →

AMCP Amicale des Cardiologues de Provence

@AMCP_cardio · X

RT @TIMIStudyGroup: Now out in print in @NEJM --> Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/yWohJAhIyv @swi…

Jan 24, 2019 · 4 shares · 132 followers View post →

Dr. Jonathan D. Parker

@JDParkerDO · X

RT @medrants: #5goodminutes today focuses on a topic that greatly interests #KashlakChief Dapagliflozin and Cardiovascular Outcomes in Type…

Jan 24, 2019 · 5 shares · 1,359 followers View post →

TIMI Study Group

@TIMIStudyGroup · X

Now out in print in @NEJM --> Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://t.co/yWohJAhIyv @swiviott

Jan 24, 2019 · 15 likes · 4 shares · 4,392 followers View post →

José García-Donaire

@josegdonaire · X

RT @TGijonConde: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/LbNtk17ihd

Jan 24, 2019 · 3 shares · 1,016 followers View post →

b. vanessa deniz

@VanessitaDeniz · X

RT @TGijonConde: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/LbNtk17ihd

Jan 24, 2019 · 3 shares · 1,385 followers View post →

Teresa Gijon Conde

@TGijonConde · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/LbNtk17ihd

Jan 24, 2019 · 4 likes · 3 shares · 1,055 followers View post →

SEH-LELHA

@SEHLELHA140_90 · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/shp8Bgt2p5

Jan 24, 2019 · 5,842 followers View post →

Aditya A Joshi

@AdvancedHFBuddy · X

RT @medrants: #5goodminutes today focuses on a topic that greatly interests #KashlakChief Dapagliflozin and Cardiovascular Outcomes in Type…

Jan 24, 2019 · 5 shares · 1,760 followers View post →

Robert Centor MD MACP

@medrants · X

#5goodminutes today focuses on a topic that greatly interests #KashlakChief Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes @NEJM https://t.co/nfqC6vVHsQ Decreased HF admissions at expense of DKA and genital infections. No impact on major CV events @thecurbsiders

Jan 24, 2019 · 7 likes · 5 shares · 17,613 followers View post →

b. vanessa deniz

@VanessitaDeniz · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 7 shares · 1,385 followers View post →

Paola Beltran Tronco

@paolabel_cardio · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 7 shares · 3,291 followers View post →

Vicente Pallares

@vic_pallares · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 7 shares · 5,417 followers View post →

Alberto Cordero

@acorderofort · X

RT @FernandoCiveir1: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 7 shares · 4,949 followers View post →

Fernando Civeira

@FernandoCiveir1 · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/Ck5V7HajJV. Bien, pero esperábamos más

Jan 24, 2019 · 13 likes · 7 shares · 346 followers View post →

Aaron Liew MB BCh, MPH, PhD

@AARONLYL · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/cBSg7INwq4

Jan 23, 2019 · 100 followers View post →

Emma Marshman

@emma_marshman · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/pTv7kkKrxN

Jan 23, 2019 · 249 followers View post →

猫になりたい薬剤師

@Vannyamoto · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM 再掲？ https://t.co/EpUG1hnsln

Jan 23, 2019 · 1 like · 1,049 followers View post →

Nirav Dhanesha

@Nirav_Dhanesha · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | NEJM https://t.co/8zMM4XOejZ

Jan 23, 2019 · 1,121 followers View post →

Jessica Grace

@Endocrine2019 · X

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. To know more about the Type 2 diabetes factors : https://t.co/IST1BvqmRs #endocrinologyconference #endocrinologycongress #endocrinologymetabolism #metabolismevent #diabetesmeeting #diabetes https://t.co/WuJlPwJ3pQ

Jan 9, 2019 · 44 followers View post →

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Key Cardiological Trials Impacting 2018 Outcomes

Advances in Managing Cardiovascular and Kidney Risks in Type 2 Diabetes